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Abstract
Introduction: Cell death is a central event in the pathogenesis of sepsis and is reflected by circulating
nucleosomes. Circulating nucleosomes were suggested to play an important role in inflammation and were
demonstrated to correlate with severity and outcome in sepsis patients. We recently showed that plasma can
release nucleosomes from late apoptotic cells. Factor VII-activating protease (FSAP) was identified to be the plasma
serine protease responsible for nucleosome release. The aim of this study was to investigate FSAP activation in
patients suffering from various inflammatory diseases of increasing severity.
Methods: We developed ELISAs to measure FSAP-C1-inhibitor and FSAP-a2-antiplasmin complexes in plasma.
FSAP-inhibitor complexes were measured in the plasma of 20 adult patients undergoing transhiatal
esophagectomy, 32 adult patients suffering from severe sepsis and 8 from septic shock and 38 children suffering
from meningococcal sepsis.
Results: We demonstrate plasma FSAP to be activated upon contact with apoptotic and necrotic cells by an assay
detecting complexes between FSAP and its target serpins a2-antiplasmin and C1-inhibitor, respectively. By means
of that assay we demonstrate FSAP activation in post-surgery patients, patients suffering from severe sepsis, septic
shock and meningococcal sepsis. Levels of FSAP-inhibitor complexes correlate with nucleosome levels and
correlate with severity and mortality in these patients.
Conclusions: These results suggest FSAP activation to be a sensor for cell death in the circulation and that FSAP
activation in sepsis might be involved in nucleosome release, thereby contributing to lethality.
Introduction
Sepsis is characterized by an extensive inflammatory
response including cytokine generation, activation of
plasmatic cascade systems and inflammatory cells lead-
ing to organ dysfunction and in many cases to death [1].
Extensive cell death as a downstream effect of these
mediators was postulated to be critically involved in the
development of organ dysfunction [2]. Indeed, several
studies in animal models for sepsis and in sepsis
patients demonstrated widespread apoptosis of lymphoid
tissue and to a lesser extent of parenchymal cells [3-5].
As a result of extensive cell death circulating nucleo-
somes could be measured in sepsis patients [6].
Moreover, nucleosomes could be detected in patients
with severe peritonitis [7]. Levels of circulating nucleo-
somes and pulmonary nucleosome levels were demon-
strated to correlate with severity and outcome in sepsis
patients [6,7]. Recent findings suggest that these circu-
lating nucleosomes play a crucial role in inflammation.
Circulating histones 3 and 4 turned out to be highly
cytotoxic and to mediate lethal effects in sepsis [8]. We
recently showed that Factor VII-activating protease
(FSAP) in plasma can remove nucleosomes from late
apoptotic cells [9,10].
FSAP, also known as plasma hyaluronic acid binding
protein 2 (HABP2), is a serine protease which circulates
in plasma as an inactive single-chain molecule of 64
kDa. It is proteolytically converted in its active two-
chain form consisting of a 50 kDa heavy and a 28 kDa
light chain connected by a disulfide bond [11]. Purified
plasma-derived FSAP is described to be susceptible to
* Correspondence: s.zeerleder@sanquin.nl
1Department of Immunopathology, Sanquin Research at CLB and
Landsteiner Laboratory of the AMC, Plesmanlaan 125, 1066 CX Amsterdam,
The Netherlands
Full list of author information is available at the end of the article
Stephan et al. Critical Care 2011, 15:R110
http://ccforum.com/content/15/2/R110
© 2011 Stephan et al.; licensee BioMed Central Ltd This is an open access article distributed under the terms of the Creative Commons
Attribution License http://creativecommons.org/licenses/by/2.0, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited
autoactivation [12]. Recently published data suggest that
purified FSAP can bind and be activated by negatively
charged polyanions such as heparin, polyphosphates,
RNA and DNA [11,13-15]. In purified systems, various
serine protease inhibitors (serpins) such as C1-inhibitor
(C1-inh), a2-antiplasmin (AP), antithrombin III (AT-III)
and plasminogen activator inhibitor-1 (PAI-1) [11,16-19]
were reported to inhibit the amidolytic activity of
plasma-derived activated FSAP. In plasma, C1-inh has
been reported to be the main inhibitor of activated
FSAP [16].
Since compounds of circulating nucleosomes induce
lethality in sepsis [8], we suggest FSAP activation in sep-
sis to be involved in nucleosome release. The aim of this
study is to investigate FSAP activation in patients suffer-
ing from inflammatory diseases of increasing severity.
Due to a lack of specific substrate and its susceptibility
for autoactivation measurement of FSAP activation is
troublesome. Therefore, we set up assays to follow
FSAP activation in plasma. We made use of the fact
that upon activation FSAP quickly forms stable covalent
complexes with its plasma inhibitors. We set up ELISAs
to measure FSAP-serpin complexes. By means of these
assays we measured FSAP activation in patients after
surgery, patients with severe sepsis, septic shock and
meningococcal sepsis.
Materials and methods
Patients
The study was approved by the institutional medical
ethics committees of the centers involved, and from all
study participants or legal representatives written
informed consent was obtained.
Healthy controls
Citrated plasma was collected from 20 healthy Dutch lab
workers.
Post-operative acute-phase response
Twenty consecutive patients with resectable adenocarci-
noma of the middle or distal esophagus or esophagogas-
tric junction were studied. Pre-operative and
peroperative investigations revealed no distant metas-
tases, and none of the patients received (neo-) adjuvant
chemotherapy or radiotherapy [20]. EDTA and citrated
blood was sampled pre-operatively (Day 0) and on days
1, 3, 5, 7, and 10 after surgery and the blood samples
were stored at -80°C until analysis.
Severe sepsis and septic shock
Patients of the medical and surgical ICU were eligible if
they met the inclusion criteria for severe sepsis and sep-
tic shock according to the definitions of the American
College of Chest Physisians (ACCP) consensus confer-
ence [21]. Patients were followed for 90 days or until
death. The sepsis patients participated in a randomized,
double-blind placebo controlled pilot study to study the
efficacy of C1-inhibitor in sepsis [22]. EDTA and
citrated blood was sampled at inclusion into the study
before the administration of C1-inhbitor or placebo,
respectively. The blood samples were stored at -80°C
until analysis. Clinical parameters, organ dysfunction
scores and acute phase parameters were assessed as
recently described [6].
Meningococcal sepsis
Children between 1 month and 18 years of age with
septic shock and petechiae/purpura were enrolled in
this study. The children were included in a rando-
mized, double-blind placebo controlled dose-finding
study to test the efficacy of plasma-derived protein C
(PC) in sepsis. Twenty-eight received PC in escalating
doses, whereas 10 received a placebo. Arterial citrated
and EDTA blood samples were collected within two
hours after admission (before the start of PC or the
placebo) and several time points afterwards and stored
at -80°C until analysis. The clinical characteristics of
these patients are described in detail elsewhere [23].
Clinical parameters, organ dysfunction scores and
acute phase parameters were assessed as recently
described [23].
Reagents
Mouse monoclonal antibodies to FSAP (anti-FSAP-4
and anti-FSAP-9), to complexed C1-inhibitor (KOK-12),
to a2-antiplasmin (AAP-20), and a control antibody
(anti-IL6) were prepared at our department (all IgG1)
[10,24]. PE-labeled rabbit-anti-mouse F(ab’)2 antibody
was obtained from Dako (Glostrup, Denmark). Iscove’s
modified Dulbecco’s medium was obtained from Bio-
Whittaker Europe (Verviers, Belgium). Fetal calf serum
was obtained from Bodinco BV (Alkmaar, The Nether-
lands). Penicillin and streptomycin were obtained from
Gibco/Invitrogen (Groningen, The Netherlands). Etopo-
side, ß-mercaptoethanol, RNase, and nitro blue tetrazo-
lium and 5’-bromo-4’-chloro-3’-indolyl phosphate (NBT/
BCIP) were obtained from Sigma (Zwijndrecht, The
Netherlands). NuPage 4 to 12% polyacrylamide gels,
sample buffer, dithiothreitol (DTT) and nitrocellulose
membranes were obtained from Invitrogen (Groningen,
The Netherlands). Western blocking reagent was
obtained from Roche Diagnostics (Mannheim, Ger-
many). Streptavidin-alkaline phosphatase was obtained
from Mabtech (Nacka Strand, Sweden). High perfor-
mance ELISA buffer (HPE) and Poly-HRP-labeled strep-
tavidin were obtained from Sanquin (Amsterdam, The
Netherlands). (3,5,3’,5’)-tetramethylbenzidine (TMB) was
obtained from Merck (Darmstadt, Germany). CNBr-acti-
vated sepharose and Protein G Sepharose was obtained
from Pharmacia Biochem (Uppsala, Sweden).
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Cell culture and induction of apoptosis and necrosis
Jurkat cells were cultured in culture medium (Iscove’s
Modified Dulbecco’s Medium (IMDM) containing 5%
(v/v) fetal calf serum (FCS), penicillin (100 IU/ml),
streptomycin (100 μg/ml) and 50 μM ß-mercaptoetha-
nol. Before apoptosis and necrosis induction, cells were
washed three times with culture medium without FCS
by centrifugation at 360 × g for 10 minutes and resus-
pended in culture medium without FCS. Cells (1 × 106
cells/ml) were incubated for 48 h with etoposide in a
final concentration of 200 μM to induce apoptosis. For
necrosis induction, cells were incubated with 0.3% H2O2
at 60°C for 60 minutes.
Recalcified plasma
In previous experiments recalcified citrated plasma was
used instead of serum clotted in the presence of cells
since microparticles in serum obscure the FACS analysis
[9]. It turned out that FSAP was not activated upon
recalcification and that recalcified citrated plasma
removed nucleosomes from apoptotic cells as efficiently
as serum [9,10]. In the text, recalcified citrated plasma is
denoted as r-plasma. Blood was obtained from healthy
donors in vials containing a final concentration of 10
mM sodium citrate and were centrifuged two times at
1,300 × g. Citrated plasma was recalcified with 20 mM
CaCl2 in a glass vial and incubated at 37°C for 30 min-
utes. Subsequently the plasma was incubated at 4°C for
30 minutes and the formed clot was removed. The r-
plasma was stored at -20°C until use. All donors were
homozygous for the wild-type form of FSAP [25].
FSAP activation in recalcified plasma
FSAP was activated as recently described [10]. Apopto-
tic, necrotic or living Jurkat cells were washed in HN-
buffer (10 mM Hepes, 140 mM NaCl, pH 7.2) and
resuspended in HN-buffer at a concentration of 2 × 106
cells/ml. RNase was added to the cells to a final concen-
tration of 10 U/ml and incubated for 30 minutes at 37°
C. R-plasma was incubated for 30 minutes at 37°C with
living, necrotic or apoptotic Jurkat cells (0.5 × 106 cells/
ml) in HN-buffer.
Binding of FSAP to cells
Apoptotic or living Jurkat cells were washed in HN-buf-
fer (10 mM Hepes, 140 mM NaCl, pH 7.2) and resus-
pended in HN-buffer at a concentration of 2 × 106
cells/ml. RNase was added to the cells to a final concen-
tration of 10 U/ml and incubated for 30 minutes at 37°
C. R-plasma was incubated for 30 minutes at 37°C with
living, necrotic or apoptotic Jurkat cells (0.5 × 106 cells/
ml) in HN-buffer. After three washes with buffer B-0.5%
BSA (10 mM Hepes, 150 mM NaCl, 5 mM KCl, 2 mM
CaCl2 and 2 mM MgCl2) cells were incubated with an
anti-FSAP antibody or an irrelevant anti-IL6 antibody
for 15 minutes. Cells were washed and stained with a
PE-labeled rabbit-anti-mouse F(ab’)2 antibody. Cells
were washed, resuspended in 150 μl buffer B- 0.5% BSA
and the samples were analyzed by flow cytometry using
BD LSRII flow cytometer (Becton Dickinson, Mountain
View, CA, USA). Cells being double positive for propi-
dium iodide and Annexin V were considered to be
apoptotic.
Immunoprecipitation and Western blotting
R-plasma was incubated with anti-FSAP-4 antibody
coupled to CNBr-activated sepharose (10 mg mAb to
500 mg of sepharose) for two hours at room tempera-
ture (RT) with gentle shaking [10]. The sepharose was
washed three times with PBS, 0.02% Tween 20, 500 mM
NaCl. Proteins attached to the beads were eluted by
heating to 90°C for 10 minutes with SDS-PAGE sample
buffer containing 50 mM dithiothreitol (DTT) and sam-
ples were applied to NuPage 4 to 12% polyacrylamide
gels. After electrophoresis, Western blotting was per-
formed on the gel according to the Western blotting
protocol Novex®. In brief, samples were blotted onto a
nitrocellulose membrane and blocked with 1% Western
blocking reagent in TBS-T (10 mM Tris pH 8.0, 150
mM NaCl, 0.1% Tween 20). Subsequently they were
incubated with biotinylated anti-FSAP-9 recognizing the
light chain of FSAP (1 μg/ml). The membranes were
washed and Streptavidin-alkaline phosphatase in TBS-T
0.5% Western blocking reagent (dilution 1:500 v/v) was
added. The blotting membranes were developed using
NBT/BCIP and the reaction was stopped with distilled
water.
Identification of plasma inhibitors of FSAP
Monoclonal anti-FSAP-4 or the irrelevant anti-IL6 was
coupled to CNBr-activated sepharose (10 mg mAb to
500 mg of sepharose). Columns were washed five times
with start buffer (10 mM Hepes, 1M NaCl, 0.02%
Tween 20, pH 7.2). R-plasma incubated with apoptotic
Jurkat cells or r-plasma incubated with buffer was
applied to the column at a flow rate of 1 ml/minute fol-
lowed by washing with five column volumes of start
buffer. Elution was performed with 0.1M glycine, 140
mM NaCl, 0.02% Tween 20, pH 2.5. The eluate was
adjusted to pH 7 with 1M tris-HCl, pH 8. Subsequently
eluates were IgG-depleted. The Protein G Sepharose
was washed three times with PBS and 1 ml of eluate
was added to 0.5 ml of Protein G Sepharose and incu-
bated head-over-head overnight at 4°C. The superna-
tants were diluted in SDS-PAGE sample buffer and
applied to NuPage 4 to 12% polyacrylamide gels. Gels
were stained with Coomassie Blue or silver staining by
using a silverstaining kit.
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MALDI-TOF peptide mass fingerprinting and
MALDI-TOF/TOF peptide sequencing analysis was per-
formed on the excised Coomassie Blue stained protein
band at Eurosequence B.V. (Meditech Center, Gronin-
gen, The Netherlands). Identification was performed by
database search using MASCOT software.
Determination of FSAP-AP and FSAP-C1-inh complexes by
ELISA
For detection of complexes of FSAP with C1-inh and
AP, 96-well microtiter plates (maxisorp, Nunc) were
coated for four hours at RT with a monoclonal antibody
specific for C1-inh in complex [24] or with a monoclo-
nal antibody against AP both at 2 μg/ml diluted in PBS.
All further incubations were performed at RT under
shaking conditions. After each step, the wells were
washed five times with washing fluid (PBS, 0.02% Tween
20) with a Microplate Autowasher (Bio-tek Instruments,
Inc. Winooski, VT, USA). All incubation steps were per-
formed in high performance ELISA buffer (HPE).
Plasma samples were added to the plate and incubated
for 60 minutes at RT. Wells were washed five times and
biotinylated anti-FSAP-4 (1 μg/ml) was added and incu-
bated for 60 minutes. After five washes streptavidin-
polymerized horseradish peroxidase (poly-HRP) conju-
gate (dilution 1:10,000 v/v) diluted in HPE was added to
each well and incubated for 20 minutes. Plates were
developed by an addition of 100 μg/ml 3,3’,5,5’-tetra-
methylbenzidine and 0.003% hydrogen peroxide in 0.11
M sodium acetate buffer pH 5.5. Coloring reaction was
stopped by adding 100 μl of 2 M H2SO4. The absor-
bance was measured at 450 nm with an ELISA plate
reader (Multiskan, Thermo Labsystems, Breda, The
Netherlands). As standard curve we used citrated r-
plasma incubated with apoptotic cells in presence of 20
mM EDTA as described in detail above. Citrated plasma
of 20 healthy donors was incubated with apoptotic cells
and FSAP-serpin complexes were measured. The med-
ian of the level of complexes in these controls was arbi-
trarily set as 0.5 AU/ml since plasma was diluted 1:1 (v/
v) with apoptotic cells. The intra- and inter assay coeffi-
cient of variation of the FSAP-AP complex ELISA was
9% and 8%, respectively. Both, the intra- and inter-assay
coefficient of variation of the FSAP-C1-inh complex
ELISA was 5%.
Nucleosome ELISA
Nucleosome levels were determined by an ELISA as
recently described [9]. Briefly, monoclonal antibody
CLB-ANA/60, which recognizes histone 3 was used as a
catching antibody. Biotinylated F(ab’)2 fragments of
CLB-ANA/58, which recognizes an epitope exposed on
complexes of histone 2A, histone 2B and dsDNA, in
combination with poly-HRP were used for detection.
Statistics
Results are expressed as mean ± SEM/median with
range. The Mann-Whitney rank-sum test was used to
assess differences between groups at a given time. Cor-
relations between variables were assessed by using
Spearman’s rank correlation corrected for multiple test-
ing. A P-value < 0.05 was considered to be statistically
significant. The cut-off values for FSAP-inhibitor com-
plexes in healthy volunteers were calculated by a
method described by Rümke et al. [26].
Results
FSAP activation by apoptotic and necrotic cells
Since incubation of plasma with apoptotic cells induces
nucleosome release via the serine protease activity of
FSAP we argued that FSAP must become activated by
interaction with those apoptotic cells [10]. We, there-
fore, analyzed whether FSAP binds to apoptotic cells.
Indeed, plasma FSAP binds strongly to apoptotic cells
whereas binding to living cells is negligible (Figure 1A).
In addition, plasma FSAP also strongly binds to necrotic
cells (data not shown). Furthermore, we could show that
interaction of r-plasma with dead cells leads to conver-
sion of single chain FSAP into active two-chain FSAP as
indicated by the appearance of the light chain at 28 kDa
(Figure 1B). No activation could be found upon incuba-
tion with living cells.
Identification of plasma inhibitors of FSAP
Since serpins form covalent complexes with their target
proteases, activated FSAP will presumably form covalent
complexes with its target inhibitors in plasma [27].
Hence, measurement of these complexes would offer an
easy and sensitive way to monitor FSAP activation in r-
plasma or plasma. To identify which serpins form com-
plexes with activated FSAP, r-plasma was incubated with
apoptotic cells and applied to an anti-FSAP affinity col-
umn. Analysis of the eluate of the r-plasma activated
with apoptotic cells by SDS-PAGE under non-reducing
conditions demonstrated an additional band at 97 kDa as
compared to the r-plasma that was not incubated with
apoptotic cells (data not shown). MALDI-TOF peptide
mass fingerprinting and MALDI-TOF/TOF peptide
sequencing analysis of the 97 kDa band resulted in a
positive identification for FSAP and a2-antiplasmin (AP)
which is described to be an inhibitor of FSAP in purified
systems [17]. Although C1-inh was reported to inhibit
activated FSAP in plasma we were not able to show C1-
inh to form complexes with FSAP on SDS-PAGE [16].
ELISA to measure FSAP-inhibitor complexes as a measure
of FSAP activation in plasma
Our results demonstrate that upon activation with apop-
totic cells FSAP forms covalent complexes with AP. To
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quantify these complexes we set up an ELISA to mea-
sure complexes between activated FSAP and AP. A
monoclonal antibody recognizing AP was used as a
catching and biotinylated anti-FSAP as detection anti-
body. Upon activation of FSAP in r-plasma, FSAP-AP
complexes could be measured by ELISA, whereas no
FSAP-AP complexes could be detected in plasma incu-
bated with buffer (Figure 2A). No signal was detected
when using an irrelevant antibody (anti-IL6) as detecting
antibody demonstrating the ELISA to specifically detect
FSAP-AP complexes (data not shown).
Since inhibition of FSAP with C1-inh was described by
others [16], we also tested whether complexes between
activated FSAP and C1-inh could be detected by ELISA.
As a catching antibody a monoclonal antibody was used
which exclusively reacts with C1-inh when complexed
with its target proteases [24] and biotinylated anti-FSAP
was used for detection. FSAP-C1-inh complexes could
be measured in r-plasma after incubation with apoptotic
cells whereas no FSAP-C1-inh complexes could be mea-
sured in r-plasma incubated with buffer (Figure 2B).
Again no signal could be detected when an irrelevant
antibody was used as detecting antibody.
These assays were used to monitor in vitro activation
of plasma FSAP by cells. Citrated plasma of 20 healthy
donors was incubated with apoptotic cells and FSAP-
inhibitor complexes were measured. The median of the
Figure 1 FSAP binding and activation upon contact with
apoptotic and necrotic cells. After incubation of r-plasma with
apoptotic and living cells, cells were incubated with an anti-FSAP
antibody. Cells were stained with a PE-labeled rabbit-anti-mouse F
(ab’)2 antibody and FSAP binding was measured with flow
cytometry (1A). Cells being double positive for propidium iodide
and Annexin V were considered to be apoptotic (not shown). After
incubation of r-plasma with apoptotic (A), necrotic (N) and living (L)
cells, FSAP was immunoprecipitated with anti-FSAP-4. R-plasma
incubated with buffer (B) was used as a negative control. Samples
were applied to SDS-PAGE 4 to 12% gel under reduced conditions
and blotted onto a nitrocellulose membrane. Detection was
performed by using biotinylated anti-FSAP-9 recognizing the light
chain (1B). scFSAP, single chain FSAP; LC, light chain.
Figure 2 ELISA’s to measure FSAP complexes with C1-inhibitor
and a2-antiplasmin. To measure complexes of FSAP with AP, AAP-
20 recognizing AP was used as catching antibody and biotinylated
anti-FSAP-4 was used for detection (A). To measure complexes of
FSAP with C1-inh, KOK12, a monoclonal antibody recognizing
complexed C1-inh was used as a catching antibody. As detection
biotinylated anti-FSAP-4 was used (B). Complexes were measured in
r-plasma and r-plasma incubated with apoptotic cells. Results are
given as mean ± SEM, (n = 3).
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level of complexes in these controls was arbitrarily set as
0.5 AU/ml (FSAP-AP 0.5 ± 0.03, FSAP-C1-inh 0.5 ±
0.04).
After incubation with apoptotic and necrotic cells
complexes with C1-inh and with AP were readily detect-
able (Figure 3). Only low levels of FSAP-inhibitor com-
plexes could be detected after incubation with living
cells. No complexes could be detected after incubation
of plasma with buffer. Together these results suggest
that measurement of complexes of FSAP with its ser-
pins, AP and C1-inh, by ELISA is a sensitive tool to
assess FSAP activation in plasma.
FSAP activation upon inflammation
Because FSAP is known to undergo autoactivation we
extensively analyzed how plasma levels of FSAP com-
plexes are influenced by sample preparation. Whereas
purified plasma-derived FSAP is susceptible for autoacti-
vation, FSAP in plasma turned out to be very resistant
to autoactivation. Even blood clotting does not activate
FSAP (data not shown). Moreover, plasma of sepsis
patients stored for three hours at room temperature
contains equal amounts of FSAP-serpin complexes as
plasma immediately after collection (data not shown).
When plasma samples of healthy donors are incubated
for three hours at 37°C also no complexes are found.
Only when plasma samples of patients were incubated
at 37°C we found an increase in complex levels.
Together these results indicate that there is no addi-
tional complex formation after collection at room
temperature, nor via auto-activation, nor via circulating
cell fragments in plasma of septic patients. We then
measured FSAP activation in citrated plasma of patients
with increasing severity of inflammation.
Patients with postoperative acute-phase response
All 20 patients undergoing transhiatal esophagectomy
were of Caucasian descent and 90% were males. The
median age was 64.6 years (range 44.6 to 78.2 yrs). Post-
operative levels of FSAP-AP and FSAP-C1-inh complexes
increased from Day 0 with highest levels of FSAP-AP on
Day 10 and of FSAP-C1-inh on Day 7 (Figure 4). FSAP
activation correlated with the increase in nucleosome
levels. The nucleosome levels correlated significantly
with FSAP-AP complexes (r = 0.5539; P < 0.0001) and
Figure 3 FSAP complexes with C1-inhibitor and a2-antiplasmin
as a measure of FSAP activation. Living (L), necrotic (N) and
apoptotic (A) cells were incubated with r-plasma for 30 minutes at
37°C. Thereafter complexes of FSAP with either AP or C1-inh were
measured by ELISA. R-plasma incubated with buffer without cells
(B) was used as a negative control. Results were expressed in AU/
ml. Plasma of 20 healthy donors was incubated with apoptotic cells
for 30 minutes at 37°C. Complexes of FSAP with either AP or C1-inh
were measured by ELISA. The median of the level of FSAP-inhibitor
complexes in these controls was arbitrarily set as 0.5 AU/ml and
used as a reference. Results are given as mean ± SEM, (n = 3).
Figure 4 FSAP-inhibitor complexes and nucleosomes in plasma
of patients undergoing a transhiatal esophagectomy. FSAP-AP
and FSAP-C1-inh complexes and nucleosomes were measured in
plasma from 20 patients undergoing esophageal resection with
proximal gastrectomy, performed by a transhiatal approach without
thoracotomy. Blood was sampled preoperatively (Day 0) and on
days 1, 3, 5, 7, 10 after surgery and six weeks postoperatively. FSAP-
inhibitor complexes were expressed as percentage of the amount
FSAP-inhibitor complexes present at day 0. The absolute values at
Day 0 were 0.51 AU/ml (range 0.03 to 4.46) for FSAP-AP and 0.06
AU/ml (0.01 to 0.40) for FSAP-C1-inh complexes. Nucleosomes were
expressed as AU/ml. Results are given as mean ± SEM.
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with FSAP-C1-inh complexes (r = 0.6440; P < 0.0001).
We also measured FSAP antigen levels in these patients.
It turned out that most patients showed a drop in FSAP
levels on Day 1, returning to normal on Day 2. This drop
is most likely not caused by consumption of FSAP but by
the fluid balance in these patients. Serum IgM levels
showed a similar drop on Day 1 (data not shown).
Patients suffering from severe sepsis and septic shock
Thirty-two patients with severe sepsis and 8 with septic
shock were enrolled: 33 males (82.5%) and 7 females
(17.5%) with a median age of 64.5 years (range 28 to 74
yrs). The clinical characteristics of these patients are
extensively described elsewhere [22]. FSAP complexes
with C1-inh and AP were elevated in 75% of the
patients. The median complex levels were significantly
higher in the sepsis patients as compared to the controls
(Figure 5). There were no significant differences in the
median levels of FSAP-inhibitor complexes between sur-
vivors (n = 27) and non-survivors (n = 13), nor for
patients suffering from severe sepsis (n = 32) and septic
shock (n = 8), respectively. FSAP antigen levels were
lower in sepsis patients as compared to healthy controls
(data not shown). Significant correlations between
FSAP-inhibitor complexes as well as with nucleosomes
could be found (Table 1). No or only weak correlation
of FSAP-inhibitor complexes with clinical parameters,
organ dysfunction scores and acute phase parameters,
such as C-reactive protein or IL-6 could be found. In
contrast, PAI-1 and C3a both being predictive para-
meters for outcome, significantly correlated with FSAP-
inhibitor complexes (r > 0.33, P < 0.05).
Patients suffering from meningococcal sepsis
Forty children with meningococcal sepsis were included
in the study [23]. From these 40 patients, citrated
plasma samples from 38 patients were available to mea-
sure FSAP-inhibitor complexes. From these 38 patients,
9 died as a result of the disease (non-survivors). The
median age of the survivors (2.7 years (range 0.3 to 16.1
yr)) was higher (P = 0.021) than non-survivors (0.9 years
(range 0.5 to 9.4 yr)). On admission, plasma samples
were available from 35 patients. Increased FSAP com-
plexes with C1-inh and AP were found in all patients at
t = 0 (Figure 6). Significant differences were found in
FSAP-AP and FSAP-C1-inh complex levels between t =
0, t = 12 h and t = 24 h compared to the levels at t = 3
months and in healthy controls. Furthermore significant
correlations between FSAP-inhibitor complexes as well
as with nucleosomes could be found (Table 2). FSAP-
inhibitor complexes increased with fatality (Figure 7).
FSAP-C1-inh complexes were significantly higher after
12 and 24 hours in non-survivors as compared to survi-
vors. FSAP-AP complexes were also higher in non-survi-
vors as compared to survivors, although the difference
was not statistically significant. FSAP antigen levels were
lower in children suffering from meningococcal sepsis
as compared to healthy controls (data not shown).
Discussion
We recently demonstrated FSAP to induce nucleosome
release from apoptotic cells [10]. There is growing evi-
dence that the content of dead cells can act as endogenous
mediators of inflammation [8]. Therefore, we were inter-
ested in measuring FSAP activation in disease. Direct mea-
surement of FSAP enzyme activity in plasma is extremely
difficult due to the lack of specific substrates. Moreover, it
Figure 5 FSAP-inhibitor complexes in plasma of sepsis patients
and healthy controls. FSAP-AP (A) and FSAP-C1-inh (B) complexes
were measured in citrated plasma from 40 patients with severe
sepsis or septic shock. FSAP-inhibitor complexes were expressed as
AU/ml. Plasma of 20 healthy donors was taken as a control. Median
values at a given time have been compared by using Mann
Whitney Rank Sum test. *** indicates a P < 0.001.
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is to be expected that the half-life of active enzyme is
extremely short, due to the presence of high plasma levels
of C1-inh and AP in the plasma. In the present paper we
demonstrate that FSAP activation in plasma can be
Figure 6 FSAP-inhibitor complexes in plasma of children with
meningococcal sepsis. FSAP-AP (A) and FSAP-C1-inh (B) complexes
were measured in citrated plasma from 38 meningococcal sepsis
patients. Blood was sampled at 0 h, 12 h, 24 h and 3 months. FSAP-
inhibitor complexes were expressed as AU/ml. Plasma of 20 healthy
donors was taken as a control. Median values at a given time have
been compared by using Mann Whitney Rank Sum test. *** indicates a
P < 0.001, ** indicates a P < 0.01.
Table 2 Correlations FSAP-inhibitor complexes and
nucleosomes in children suffering from meningococcal
sepsis
FSAP-AP FSAP-C1-inh
r P r P
FSAP-AP - - 0.521 0.001
FSAP-C1-inh 0.521 0.001 - -
Nucleosomes 0.717 < 0.0001 0.616 < 0.0001
Correlations were calculated by using Spearman rank sum test and corrected
for multiple testing. A P-value < 0.05 was considered to be statistically
significant.
Abbreviations: AP, a2-antiplasmin; C1-inh, C1-inhibitor; FSAP: factor VII-
activating protease.
Figure 7 FSAP-inhibitor complexes in plasma of survivors and
non-survivors of meningococcal sepsis. FSAP-AP (A) and FSAP-
C1-inh (B) complexes were measured in citrated plasma from
survivors and non-survivors of meningococcal sepsis. Blood was
sampled at 0 h, 12 h and 24 h. FSAP-inhibitor complexes were
expressed as AU/ml. The values are indicated by mean values ±
SEM. Median values at a given time have been compared by using
Mann Whitney Rank Sum test. * indicates P < 0.05.
Table 1 Correlations FSAP-inhibitor complexes and
nucleosomes in patients suffering from severe sepsis and
septic shock
FSAP-AP FSAP-C1-inh
r P r P
FSAP-AP - - 0.905 < 0.0001
FSAP-C1-inh 0.905 < 0.0001 - -
Nucleosomes 0.427 0.006 0.443 0.004
Correlations were calculated by using Spearman rank sum test and corrected
for multiple testing. A P-value < 0.05 was considered to be statistically
significant.
Abbreviations: AP, a2-antiplasmin; C1-inh, C1-inhibitor; FSAP: factor VII-
activating protease.
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monitored by assays detecting complexes between FSAP
and its target serpins AP and C1-inh. We used these
assays to demonstrate FSAP activation in post-surgery
patients, patients suffering from severe sepsis, septic shock
and meningococcal sepsis.
In purified systems C1-inh and AP were reported to
be the main inhibitors of activated FSAP [11,16,17]. In
plasma only C1-inh was demonstrated to be an inhibitor
of FSAP [16]. Serpins form covalent complexes with
their target proteases [27,28]. Therefore, FSAP in plasma
is expected to form covalent complexes with its inhibi-
tors upon activation. We showed by affinity purification
and mass spectrometry analysis, that FSAP in plasma
forms a complex with AP upon activation with apopto-
tic cells. In order to set up a more simple and sensitive
method we tried to measure FSAP-inhibitor complexes
by ELISA. Indeed, we were able to detect FSAP-AP
complexes in plasma which is incubated with apoptotic
cells. Since no FSAP complexes with AP could be
detected in plasma which is not activated with apoptotic
cells or by using an irrelevant detection antibody the
ELISA specifically detects complexes of FSAP with AP.
Although we were not able to detect FSAP-C1-inh com-
plexes after affinity purification by SDS-PAGE, these
complexes could be detected by ELISA. This might indi-
cate that ELISA is a more sensitive method than affinity
purification and SDS-PAGE or that the FSAP-C1-inh
complex is dissociated upon SDS-PAGE.
FSAP strongly binds to apoptotic as well as to necrotic
cells and no binding to living cells is seen. Probably this
binding leads to activation of FSAP as shown by Wes-
tern blotting and complex formation. Living cells lead to
some complex formation, which is very likely due to the
presence of dead cells in cultured cells. Indeed Figure
1A shows that living jurkat cells contain a fraction of
dead cells that bind FSAP. The fact that FSAP activation
by living cells is not seen in Western blot reflects the
much higher sensitivity of the complex ELISAs to detect
FSAP activation. To which structure FSAP binds, and
how FSAP activation is achieved, is not clear yet. RNA,
and to a lesser extent also DNA, is reported to activate
FSAP [13,15]. We routinely use RNase-treated cells to
induce FSAP activation. RNase treatment improves the
specificity of the Propidium Iodide staining used in the
Nucleosome releasing factor assay [10]. No differences
in FSAP activation could be found between RNase trea-
ted and untreated cells suggesting that FSAP activation
by RNA in our system is rather unlikely. Our results
further show that when in plasma or serum, FSAP is a
robust stable molecule. Once purified it becomes very
susceptible to auto-activation. For a molecule described
to be involved in coagulation and fibrinolysis is seems
odd that even total coagulation of blood does not lead
to FSAP activation.
Our results indicate FSAP activation to be a useful tool
to measure cell death in circulation. Of course some ques-
tions remain unanswered. How exactly is FSAP activated,
how much FSAP remains associated with dead cells and
how much is released in the circulation? Another question
is what determines the inhibitor specificity. Do different
types of activation lead to different inhibitor complexes
and to what extent is inhibitor concentration important?
Notwithstanding these questions we think that the newly
developed complex assays could be useful in understand-
ing inflammation such as sepsis. Cell death is a central
event in the pathogenesis of sepsis and is reflected by cir-
culating nucleosomes [5,6]. Indeed, FSAP activation could
be detected in severe sepsis, septic shock and meningococ-
cal sepsis and significantly correlated with nucleosome
levels. Even in a model of “a low grade inflammation”
FSAP activation could be detected and significantly corre-
lated with nucleosome levels, whereas FSAP complexes
with C1-inh or AP could not be detected in healthy con-
trols. Altogether these results suggest FSAP activation to
be a sensor for cell death in circulation.
FSAP activation increases with the severity of inflamma-
tion as shown by FSAP-inhibitor complexes, which corre-
late with the increase in disease severity with the lowest
level in post surgery and higher levels in adult patients
with sepsis and children suffering from meningococcal
sepsis. FSAP-inhibitor complex levels in meningococcal
sepsis were significantly higher in survivors than in non-
survivors, although the non-survivor group was small.
FSAP-inhibitor complex levels in adult sepsis increased
with the severity of inflammation as evidenced by signifi-
cant correlations with inflammatory markers (C3a, PAI-1)
but did not discriminate for fatality. The discrepancy
between adults and children might be explained by the
fact that the sepsis patients form a heterogeneous group
composed of patients from surgical as well as from medi-
cal ICU (n = 22 vs n = 18), whereas the children suffering
from meningococcal sepsis form a considerably more
homogenous population with a clear-cut onset of sepsis.
Conclusions
In summary, we show that FSAP in plasma is activated
upon contact with dead cells and this activation can be
followed by measuring FSAP-AP and FSAP-C1-inh
complexes in plasma by ELISA. We demonstrate FSAP
activation in adults suffering from sepsis and children
with meningococcal sepsis which increases with the
severity of inflammation. Our results suggest that FSAP
activation in sepsis might be involved in nucleosome
release thereby contributing to lethality.
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inhibitor; DTT: dithiothreitol; FCS: fetal calf serum; FSAP: Factor VII-activating
protease; HABP2: hyaluronic acid binding protein 2; HPE: high performance
ELISA; NBT: nitro blue tetrazolium; PAI-1: plasminogen activator inhibitor-1;
PC: plasma-derived protein C; r-plasma: recalcified citrated plasma; TMB:
(3,5,3’,5’)-tetramethylbenzidine.
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